Adalimumab and methotrexate (MTX) data divided into four groups at start of adalimumab (Ada)
| Ada+10 mg MTX (36) | Ada+15 mg MTX (104) | Ada+20 mg MTX (85) | Ada+25 mg MTX (146) | p Value | |
|---|---|---|---|---|---|
| Mean age (SD), years | 56.5 (12.9) | 54.7 (11.9) | 54.1 (12.4) | 50.6 (13.1) | 0.015 |
| Female | 77.8% (28) | 69.2% (72) | 64.7% (85) | 69.9% (102) | 0.556 |
| Median disease duration (IQR) | 5.4 (2.6–10.2) | 5.1 (1.9–11.2) | 5.1 (1.8–13.4) | 3.2 (0.9–8.1) | 0.027 |
| RF+ | 80.6% (29) | 76.0% (76) | 68.3% (56) | 63.8% (90) | 0.099 |
| Erosive | 72.4% (21) | 72.6% (61) | 66.7% (42) | 51.1% (48) | 0.001 |
| No. of DMARDs* | 0.802 | ||||
| 1 | 58.3% (21) | 65.4% (68) | 63.5% (54) | 58.9% (86) | |
| 2 | 33.3% (12) | 27.9% (29) | 30.6% (26) | 34.2% (50) | |
| 3 | 5.6% (2) | 6.7% (7) | 5.9% (5) | 5.5% (8) | |
| 4 | 2.8% (1) | 0.0% (0) | 0.0% (0) | 1.4% (2) | |
| DAS28 (SD) | 5.15 (1.29) | 4.76 (1.29) | 4.60 (1.40) | 4.55 (1.34) | 0.142 |
| HAQ-DI (SD) | 1.35 (0.65) | 1.22 (0.58) | 1.13 (0.62) | 1.17 (0.61) | 0.410 |
| Oral MTX | 62.9% (22) | 52.4% (54) | 54.1% (46) | 51.4% (75) | 0.671 |
The 444 patients received the following MTX doses: 2.5 mg (1), 5 mg (6), 7.5 mg (10), 10 mg (36), 12.5 mg (11), 15 mg (104), 17.5 mg (2), 20 mg (85), 22.5 mg (0), 25 mg (146), 27.5 mg (0), 30 mg (19) and ≥35 mg (10).
*Number of DMARDs as comedication next to adalimumab. This includes methotrexate. Other possible DMARDs are sulfasalazine, hydroxychloroquine, leflunomide, aurothiomalaat and azathioprine.
DAS28, disease activity score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, health assessment questionnaire disability index; RF+, rheumatoid factor positive.